Dimensional Fund Advisors LP Has $1.29 Million Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Dimensional Fund Advisors LP decreased its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 50.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 33,696 shares of the company's stock after selling 34,448 shares during the period. Dimensional Fund Advisors LP's holdings in Apellis Pharmaceuticals were worth $1,293,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sierra Summit Advisors LLC acquired a new position in shares of Apellis Pharmaceuticals in the 4th quarter valued at about $222,000. Vanguard Group Inc. boosted its stake in Apellis Pharmaceuticals by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 9,555,678 shares of the company's stock valued at $572,003,000 after purchasing an additional 85,701 shares during the period. Future Financial Wealth Managment LLC acquired a new position in Apellis Pharmaceuticals during the 1st quarter valued at about $29,000. Hennion & Walsh Asset Management Inc. boosted its stake in Apellis Pharmaceuticals by 14.4% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 14,068 shares of the company's stock valued at $827,000 after purchasing an additional 1,766 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its position in shares of Apellis Pharmaceuticals by 94.8% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 115,453 shares of the company's stock worth $6,786,000 after buying an additional 56,178 shares in the last quarter. Hedge funds and other institutional investors own 96.29% of the company's stock.

Insider Buying and Selling at Apellis Pharmaceuticals

In other news, Director A. Sinclair Dunlop sold 37,000 shares of the company's stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the transaction, the director now directly owns 100,000 shares of the company's stock, valued at approximately $3,623,000. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 6.80% of the company's stock.

Analysts Set New Price Targets

A number of research firms have commented on APLS. The Goldman Sachs Group boosted their price target on shares of Apellis Pharmaceuticals from $66.00 to $74.00 and gave the stock a "buy" rating in a research report on Friday, August 9th. JPMorgan Chase & Co. lowered their price objective on shares of Apellis Pharmaceuticals from $64.00 to $57.00 and set an "overweight" rating on the stock in a research report on Friday, September 13th. Mizuho lowered their price objective on shares of Apellis Pharmaceuticals from $42.00 to $39.00 and set a "neutral" rating on the stock in a research report on Friday, September 20th. Needham & Company LLC reissued a "buy" rating and issued a $85.00 target price on shares of Apellis Pharmaceuticals in a research report on Friday, September 20th. Finally, Wells Fargo & Company cut their target price on shares of Apellis Pharmaceuticals from $47.00 to $43.00 and set an "equal weight" rating for the company in a research note on Tuesday, September 24th. Four equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $70.20.

Apellis Pharmaceuticals Stock Performance

NASDAQ:APLS traded up $0.47 on Friday, hitting $27.14. The stock had a trading volume of 2,445,949 shares, compared to its average volume of 1,653,206. The business's 50-day simple moving average is $34.92 and its two-hundred day simple moving average is $40.44. The company has a quick ratio of 4.18, a current ratio of 5.08 and a debt-to-equity ratio of 1.73. Apellis Pharmaceuticals, Inc. has a 52-week low of $26.28 and a 52-week high of $73.80. The stock has a market cap of $3.29 billion, a price-to-earnings ratio of -7.84 and a beta of 0.87.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.03. The company had revenue of $199.70 million for the quarter, compared to analyst estimates of $190.89 million. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The firm's quarterly revenue was up 110.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.02) EPS. As a group, research analysts predict that Apellis Pharmaceuticals, Inc. will post -1.37 earnings per share for the current year.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).